back to all publications

Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system

CSS Publication Number
CSS24-29
Full Publication Date
June, 2024
Abstract

Health care is a major source of greenhouse gas emissions, leading to climate change and public health harms. Changes are needed to improve the environmental sustainability of health-care practices, but such changes should not sacrifice patient outcomes or financial sustainability. Alternative dosing strategies that reduce the frequency with which specialty drugs are administered, without sacrificing patient outcomes, are an attractive possibility for improving environmental sustainability. We sought to inform environmentally sustainable cancer care by estimating and comparing the environmental and financial effects of alternative, clinically equivalent strategies for pembrolizumab administration.

Co-Author(s)
Alex K Bryant
Jacqueline R Lewy
Daniel Bressler
Derek J Gyori
Julie A Moeller
Sofia I Jacobson
Eve A Kerr
Nithya Ramnath
Michael D Green
A Mark Fendrick
Zoey Chopra
Brian G Bazzell
Research Areas
Consumer Products & Packaging
Keywords

health care, greenhouse gas emissions, climate change, public health, Environmental sustainability

Publication Type
Journal Article
Digital Object Identifier
https://doi.org/10.1016/S1470-2045(24)00200-6
Full Citation

Bryant, A. K., Lewy, J. R., Bressler, R. D., Chopra, Z., Gyori, D. J., Bazzell, B. G., Moeller, J. A., Jacobson, S. I., Fendrick, A. M., Kerr, E. A., Ramnath, N., Green, M. D., Hofer, T. P., Vaishnav, P., & Strohbehn, G. W. (2024). Projected environmental and public health benefits of extended-interval dosing: An analysis of pembrolizumab use in a US national health system. *The Lancet Oncology, 25*(6), 802-810. https://doi.org/10.1016/S1470-2045(24)00200-6